CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2006-02-22): Britain's NICE backs Roche's Pegasys and Gilead's Hepsera for hepatitis B

Regulatory

Britain's NICE backs Roche's Pegasys and Gilead's Hepsera for hepatitis B

Last Updated: 2006-02-22 11:00:34 -0400 (Reuters Health)

LONDON (APM) - Britain's health cost-effectiveness watchdog, NICE, on Wednesday backed first-line use of Roche's Pegasys (peginterferon alfa-2a) and second-line use of Gilead's Hepsera (adefovir dipivoxil) for the treatment of chronic hepatitis B.

In a statement, the National Institute for Health and Clinical Excellence said peginterferon alfa-2a was "recommended as an option for the initial treatment of adults with chronic hepatitis B within its licensed indications".

Adefovir dipivoxil was recommended if treatment with interferon alfa or peginterferon alfa-2a was unsuccessful or was poorly tolerated or contraindicated. It should not normally be given before treatment with lamivudine.

The guidance does not apply to patients known to be co-infected with hepatitis C, hepatitis D or HIV, NICE added.

The Department of Health estimates that 180,000 people in the UK are affected by chronic hepatitis B though only a small fraction of those with the condition know they have it.

"We hope that today's excellent guidance will prompt a public health campaign that will alert people to this condition and encourage them to get tested, diagnosed, treated and protected," said Professor Roger Williams, Director of the Foundation for Liver Research, in the NICE statement.

Globally, Pegasys had sales of 1.4 billion Swiss francs (0.9 billion euros) in 2005 and Roche forecasts peak annual sales of around 2 billion francs. Hepsera sales rose 43% to $51.2 million in the fourth quarter of 2005.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.